This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
ECDC publishes a protocol developed for the surveillance of Clostridioides (Clostridium) difficile infections (CDI) to address the lack of standardised surveillance of CDI in EU Member States.
The main objective of this guidance is to provide scientific advice, based on an evidence-based assessment of targeted public health interventions, to facilitate effective screening and vaccination for priority infectious diseases among newly arrived migrant populations to the EU/EEA. It is intended to support EU/EEA Member States to develop national strategies to strengthen infectious disease prevention and control among migrants and meet the health needs of these populations.
This updated protocol prescribes the methodology, and provides the data collection tools required to achieve the objectives of European surveillance of CDIs.
This document is intended for hospital staff that use HelicsWin.Net to collect or administer data collected using ECDC’s HAI-Net surveillance of healthcare-associated infections methods (HAINet PPS and ICU).
This document establishes a protocol for the case detection, laboratory diagnosis and environmental testing of Mycobacterium chimaera infections which are potentially associated with heater-cooler units.
This protocol for harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter from human isolates aims to increase the quality and comparability of antimicrobial resistance data collected at the EU level from different Member States. It is primarily targeted to the National Public Health Reference Laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This document is intended for hospital staff that use HelicsWin.Net to collect or administer data collected during the ECDC Point Prevalence Survey (PPS) of healthcare-associated infections (HAI) and antimicrobial use (AMU) in acute care hospitals.